Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Genfit SA ( (GNFT) ) has shared an announcement.
On July 8, 2025, GENFIT announced the half-year report of its liquidity contract with Crédit Industriel et Commercial, revealing that as of June 30, 2025, the liquidity account held 201,100 shares and €398,484.67. During the first half of 2025, the company executed significant trading activities, with 1,412,901 shares bought and 1,419,301 shares sold, indicating active engagement in the market. This report provides insights into GENFIT’s financial operations and market activities, reflecting its strategic positioning and potential implications for stakeholders.
The most recent analyst rating on (GNFT) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Genfit SA stock, see the GNFT Stock Forecast page.
Spark’s Take on GNFT Stock
According to Spark, TipRanks’ AI Analyst, GNFT is a Neutral.
Genfit SA’s overall stock score reflects a mix of financial recovery and technical challenges. The company’s strong revenue growth and return to profitability are significant positives, but these are tempered by high valuation metrics and bearish technical indicators. The lack of earnings call data or notable corporate events leaves these areas unaddressed, focusing the analysis on financial performance and technical aspects.
To see Spark’s full report on GNFT stock, click here.
More about Genfit SA
GENFIT is a biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases. The company has a strong research and development portfolio, particularly in Acute-on-Chronic Liver Failure (ACLF), and has successfully achieved accelerated approval for its drug Iqirvo® (elafibranor) for Primary Biliary Cholangitis (PBC). GENFIT also has a diagnostic franchise and is headquartered in Lille, France, with offices in Paris, Zurich, and Cambridge, MA.
Average Trading Volume: 10,921
Technical Sentiment Signal: Sell
Current Market Cap: $189.2M
See more data about GNFT stock on TipRanks’ Stock Analysis page.